Michel Dahan's most recent trade in Akebia Therapeutics Inc. was a trade of 34,840 Common Stock done at an average price of $1.3 . Disclosure was reported to the exchange on May 13, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 13 May 2024 | 34,840 | 672,092 (0%) | 0% | 1.3 | 43,898 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.58 per share. | 29 Feb 2024 | 8,661 | 706,932 (0%) | 0% | 1.6 | 13,684 | Common Stock |
Akebia Therapeutics Inc. | Dahan Michel | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.52 per share. | 27 Feb 2024 | 10,744 | 715,593 (0%) | 0% | 1.5 | 16,331 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 224,000 | 224,000 | - | - | Stock Option (Right to buy) | |
Akebia Therapeutics Inc. | Dahan Michel | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 149,300 | 726,337 (0%) | 0% | 0 | Common Stock | |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 200,000 | 669,515 (0%) | 0% | 0 | Common Stock | |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to buy) | |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.22 per share. | 24 May 2023 | 95,478 | 574,037 (0%) | 0% | 1.2 | 116,760 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2023 | 200,000 | 469,515 (0%) | 0% | 0 | Common Stock | |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 01 Mar 2023 | 10,476 | 271,393 (0%) | 0% | 0.9 | 9,193 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 01 Mar 2023 | 8,058 | 281,869 (0%) | 0% | 0.9 | 7,071 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 01 Mar 2023 | 1,878 | 269,515 (0%) | 0% | 0.9 | 1,648 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.81 per share. | 27 Feb 2023 | 10,090 | 289,927 (0%) | 0% | 0.8 | 8,205 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to buy) | |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 50,000 | 308,995 (0%) | 0% | 0 | Common Stock | |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 28 Feb 2022 | 6,873 | 295,249 (0%) | 0% | 2.2 | 14,919 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 28 Feb 2022 | 6,873 | 302,122 (0%) | 0% | 2.2 | 14,919 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.15 per share. | 28 Feb 2022 | 6,555 | 258,995 (0%) | 0% | 2.2 | 14,125 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 28 Feb 2022 | 1,232 | 297,017 (0%) | 0% | 2.2 | 2,674 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 01 Apr 2021 | 1,211 | 265,550 (0%) | 0% | 3.4 | 4,117 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 11,648 | 266,761 (0%) | 0% | 0 | Common Stock | |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 110,000 | 110,000 | - | - | Employee Stock Option (Right to buy) | |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 62,000 | 269,660 (0%) | 0% | 0 | Common Stock | |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 26 Feb 2021 | 7,945 | 255,113 (0%) | 0% | 3.4 | 26,982 | Common Stock |
Akebia Therapeutics Inc. | Michel Dahan | SVP, Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 26 Feb 2021 | 6,602 | 263,058 (0%) | 0% | 3.4 | 22,421 | Common Stock |